Assessing iPSC Morphology

(3:9)

SPS 2018: Implementing Human iPSC-derived Cells in Early Safety Assessment \u0026 Disease Modeling

(35:21)

Induced Pluripotent Stem Cell iPSC

(5:4)

Assessing genetic stability of iPSC derived allogenic cell therapy | Parimal Pande | Janssen

(25:52)

Passaging iPSCs with ReLeSR

(3:46)

Live Staining of iPSCs

(8:36)

Assessing the Quality of your iPSC Culture

(1:10)

How to Maintain and Assess Morphology of Human Pluripotent Stem Cells (hPSCs) in mTeSR™ Plus

(3:36)

Exploring the Role of iPSC-cardiomyocytes in Drug Discovery and Safety Assessment

(57:1econd)

Passaging iPSCs

(6:6)

WEBINAR: Exploring the Role of iPSC-Cardiomyocytes in Drug Discovery and Safety Assessment

(57:1econd)

HipSci: Troubleshooting iPSC culture

(22:39)

Utilizing Stem Cell-derived Cardiomyocytes for Early Safety Screening - Webinar Presentation

(53:40)

Passaging Human iPS Cells | REPROCELL

(7:26)

Achieving clinical quality for human iPSC generation and expansion

(28:6)

Functional Assessment of Cardiomyocytes Derived from Human Pluripotent Stem Cells

(24:16)

A Guide to Passaging Human Pluripotent Stem Cells Using mTeSR®1

(5:58)

iPSC Reprogramming Challenges and Solutions

(59:49)

Achieving clinical quality for human iPSC generation and expansion

(43:44)

High-Throughput Assessment of Compound-Induced Cardiotoxicity Using Human iPSC-Derived Cardiomyocyte

(50:56)